InvestorsHub Logo
Followers 32
Posts 2200
Boards Moderated 0
Alias Born 09/01/2020

Re: meirluc post# 605767

Thursday, 06/29/2023 11:59:55 PM

Thursday, June 29, 2023 11:59:55 PM

Post# of 701201
Sure, it will grow some, but it will never scale beyond a few million per quarter.

Firstly, the main bottleneck currently is KCL even if they had sufficient demand. It’s the only site doing leukapheresis for DCVAX-L compassionate use and they can only handle so many GBM patients per month. Why aren’t other UK trial sites participating in the specials program?

Secondly, how many patients will pay $200k out of pocket?

Thirdly, what percentage of neurosurgeons outside the ph 3 trial are deeply familiar with DCVAX-L results and not attached to other technology platform or trials?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News